Incorporating the patient experience in real-world evidence studies: an interview with Emily Hardie, Kyowa Kirin International and Susan Thornton, Cutaneous Lymphoma Foundation

Fostering meaningful partnerships in drug development is key, especially when this involves the company and patient organizations. Such collaborations ensure that the patient perspective is integrated into every stage of the process, particularly in study design. By working together, companies and patient groups can address unmet needs more effectively, enhance the relevance of research outcomes, and ultimately improve the overall quality of care. In this interview, we speak with Susan Thornton (Cutaneous Lymphoma Foundation) and Emily Hardie (Kyowa Kirin International, UK) to learn more about their collaboration in the design of the PROSPER study. This real-world study aims to understand...